Mark Penney

1.6k total citations
18 papers, 1.1k citations indexed

About

Mark Penney is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Mark Penney has authored 18 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 4 papers in Oncology and 4 papers in Hematology. Recurrent topics in Mark Penney's work include Glioma Diagnosis and Treatment (3 papers), Computational Drug Discovery Methods (3 papers) and Prion Diseases and Protein Misfolding (2 papers). Mark Penney is often cited by papers focused on Glioma Diagnosis and Treatment (3 papers), Computational Drug Discovery Methods (3 papers) and Prion Diseases and Protein Misfolding (2 papers). Mark Penney collaborates with scholars based in United Kingdom, United States and Sweden. Mark Penney's co-authors include David A. Hilton, Diane Ritchie, Linda McCardle, James W. Ironside, P. G. Edwards, Doha Hegazy, Azra C. Ghani, Paul Newbold, René van der Merwe and Jörn Drappa and has published in prestigious journals such as Blood, Gastroenterology and The American Journal of Surgical Pathology.

In The Last Decade

Mark Penney

18 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark Penney United Kingdom 15 507 209 207 134 100 18 1.1k
Kamala Vanarsa United States 17 225 0.4× 71 0.3× 481 2.3× 86 0.6× 32 0.3× 45 1.1k
Xia Bai China 19 394 0.8× 68 0.3× 197 1.0× 87 0.6× 13 0.1× 108 1.2k
Rongqing Guo United States 8 816 1.6× 75 0.4× 231 1.1× 127 0.9× 22 0.2× 9 1.4k
Marisa Cañadas‐Garre Spain 19 435 0.9× 95 0.5× 101 0.5× 66 0.5× 11 0.1× 44 1.0k
Antonella Spila Italy 25 500 1.0× 79 0.4× 291 1.4× 144 1.1× 27 0.3× 64 1.6k
Samina Y. Khan United States 16 228 0.4× 141 0.7× 175 0.8× 61 0.5× 13 0.1× 27 1.2k
Hui‐Jia Dong United States 12 468 0.9× 73 0.3× 194 0.9× 154 1.1× 10 0.1× 16 1.1k
Silke Roedder United States 12 403 0.8× 64 0.3× 120 0.6× 143 1.1× 16 0.2× 17 1.1k
Tianbo Jin China 16 374 0.7× 134 0.6× 130 0.6× 98 0.7× 8 0.1× 95 882
Csilla Sipeky Hungary 18 183 0.4× 131 0.6× 187 0.9× 42 0.3× 11 0.1× 39 723

Countries citing papers authored by Mark Penney

Since Specialization
Citations

This map shows the geographic impact of Mark Penney's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Penney with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Penney more than expected).

Fields of papers citing papers by Mark Penney

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Penney. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Penney. The network helps show where Mark Penney may publish in the future.

Co-authorship network of co-authors of Mark Penney

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Penney. A scholar is included among the top collaborators of Mark Penney based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Penney. Mark Penney is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Penney, Mark, Juliana Candido, Jim Eyles, et al.. (2024). A mechanistic PK/PD model of AZD0171 (anti‐LIF) to support Phase II dose selection. CPT Pharmacometrics & Systems Pharmacology. 13(10). 1670–1681. 2 indexed citations
2.
Shah, Mittal, Carl Doyle, Kevin Greenslade, et al.. (2021). Recombinant sclerostin inhibits bone formation in vitro and in a mouse model of sclerosteosis. Journal of Orthopaedic Translation. 29. 134–142. 14 indexed citations
3.
King, Lloyd, et al.. (2020). Evaluation of In Vitro Models for Assessment of Human Intestinal Metabolism in Drug Discovery. Drug Metabolism and Disposition. 48(11). 1169–1182. 22 indexed citations
4.
Spilker, Mary E., Richard Zang, Handan He, et al.. (2019). Applications of Quantitative Systems Pharmacology in Model‐Informed Drug Discovery: Perspective on Impact and Opportunities. CPT Pharmacometrics & Systems Pharmacology. 8(11). 777–791. 60 indexed citations
5.
Cucurull-Sanchez, L., Michael J. Chappell, Vijayalakshmi Chelliah, et al.. (2019). Best Practices to Maximize the Use and Reuse of Quantitative and Systems Pharmacology Models: Recommendations From the United Kingdom Quantitative and Systems Pharmacology Network. CPT Pharmacometrics & Systems Pharmacology. 8(5). 259–272. 42 indexed citations
6.
Nijsen, Marjoleen, Erica L. Bradshaw‐Pierce, Jason R. Chan, et al.. (2018). Preclinical QSP Modeling in the Pharmaceutical Industry: An IQ Consortium Survey Examining the Current Landscape. CPT Pharmacometrics & Systems Pharmacology. 7(3). 135–146. 64 indexed citations
7.
Sands, Bruce E., Jingjing Chen, Brian G. Feagan, et al.. (2017). Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn’s Disease: A Phase 2a Study. Gastroenterology. 153(1). 77–86.e6. 223 indexed citations
8.
Calverley, Peter M.A., Sanjay Sethi, Michelle Dawson, et al.. (2017). A randomised, placebo-controlled trial of anti–interleukin-1 receptor 1 monoclonal antibody MEDI8968 in chronic obstructive pulmonary disease. Respiratory Research. 18(1). 153–153. 74 indexed citations
9.
Almquist, J.O., Mark Penney, S. KENNETH PEHRSSON, et al.. (2016). Unraveling the pharmacokinetic interaction of ticagrelor and MEDI2452 (Ticagrelor antidote) by mathematical modeling. CPT Pharmacometrics & Systems Pharmacology. 5(6). 313–323. 8 indexed citations
10.
11.
Buchanan, Andrew, Philip M. Newton, S. KENNETH PEHRSSON, et al.. (2015). Structural and functional characterization of a specific antidote for ticagrelor. Blood. 125(22). 3484–3490. 64 indexed citations
12.
Nyman, Elin, et al.. (2014). Effects of IL‐1β–Blocking Therapies in Type 2 Diabetes Mellitus: A Quantitative Systems Pharmacology Modeling Approach to Explore Underlying Mechanisms. CPT Pharmacometrics & Systems Pharmacology. 3(6). 1–8. 17 indexed citations
13.
Penney, Mark & Balaji Agoram. (2013). At the bench: the key role of PK–PD modelling in enabling the early discovery of biologic therapies. British Journal of Clinical Pharmacology. 77(5). 740–745. 9 indexed citations
14.
15.
Hilton, David A., Mark Penney, P. G. Edwards, et al.. (2004). Specificity of lymphoreticular accumulation of prion protein for variant Creutzfeldt–Jakob disease. Journal of Clinical Pathology. 57(3). 300–302. 51 indexed citations
16.
Hilton, David A., Azra C. Ghani, P. G. Edwards, et al.. (2004). Prevalence of lymphoreticular prion protein accumulation in UK tissue samples. The Journal of Pathology. 203(3). 733–739. 293 indexed citations
17.
Hilton, David A., et al.. (2002). Evaluation of Molecular Markers in Low-Grade Diffuse Astrocytomas. The American Journal of Surgical Pathology. 26(4). 472–478. 23 indexed citations
18.
Hilton, David A., et al.. (2002). Expression of hypoxia‐inducible factor 1α in tumours of patients with glioblastoma. Neuropathology and Applied Neurobiology. 28(3). 210–217. 75 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kamala Vanarsa Breakdown of academic impact, for papers by Xia Bai Breakdown of academic impact, for papers by Rongqing Guo Breakdown of academic impact, for papers by Marisa Cañadas‐Garre Breakdown of academic impact, for papers by Antonella Spila Breakdown of academic impact, for papers by Samina Y. Khan Breakdown of academic impact, for papers by Hui‐Jia Dong Breakdown of academic impact, for papers by Silke Roedder Breakdown of academic impact, for papers by Tianbo Jin Breakdown of academic impact, for papers by Csilla Sipeky
Rankless by CCL
2026